ACAD250117C11000
- 0.00
- 0.000.00%
ACADIA Pharmaceuticals Newsroom
Acadia Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025
ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Express News | ACADIA Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Express News | ACADIA Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million
Acadia Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million
Express News | ACADIA Pharmaceuticals Appoints Thomas Garner Chief Commercial Officer
Acadia Pharmaceuticals Appoints Thomas Garner Chief Commercial Officer
Why Acadia Pharmaceuticals (ACAD) Is a Top Momentum Stock for the Long-Term
Implied Volatility Surging for ACADIA Pharmaceuticals (ACAD) Stock Options
Baird Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Maintains Target Price $28
ACAD Signs License Deal With Saniona for Rights to Neurology Drug
JMP Securities Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Maintains Target Price $39
JMP Securities Keeps Their Buy Rating on ACADIA Pharmaceuticals (ACAD)
Acadia Signs Licensing Deal for Essential Tremor Drug Candidate
Acadia Pharmaceuticals Announces Exclusive License Agreement With Saniona For SAN711; Under The Terms Of The License Agreement, Saniona Will Receive $28M Upfront Plus Potential Milestone Payments Of Up To $582M
Express News | ACADIA Pharmaceuticals Inc - Saniona to Receive $28 Million Upfront Plus up to $582 Million in Milestones
Express News | ACADIA Pharmaceuticals Inc - to Initiate Phase 2 Study of San711 in 2026
Express News | ACADIA Pharmaceuticals Announces Exclusive License Agreement With Saniona for San711
Acadia Pharmaceuticals Announces Exclusive License Agreement With Saniona for SAN711